Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EpiPen Price Hearing: House Plays Bootleg Tape Of Shkreli Event

Executive Summary

Another election year hearing on drug prices yielded more of the same discussions on price hikes and FDA's approval process.

Advertisement

Related Content

Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict
Lilly CEO Breaks From PhRMA, Innovators With Support For CREATES Act
Trump Slams FDA Regulations In Joint Session Of Congress
Pricing Transparency Policies Not Suited To Generics, GPhA Argues
A Tale Of Two Committees: Which Probed EpiPen Better?
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119182

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel